Palisade Bio Plunges 11.48% Despite Positive Trial Results

On July 24, 2025, Palisade Bio's stock experienced a significant drop of 11.48% in pre-market trading.

Palisade Bio recently reported positive Phase 1a results for PALI-2108, a first-in-class terminal ileum and colon-targeted PDE4 B/D inhibitor designed for fibrostenotic Crohn's disease. This development is a significant milestone for the company, as it demonstrates the potential efficacy of their novel therapeutic approach.

The company also announced an agreement with several accredited investors to exercise existing warrants, raising approximately $3.9 million. This capital infusion is expected to support the company's working capital and general corporate purposes, providing a financial boost to continue its research and development efforts.

Additionally, Palisade Bio participated in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference, showcasing its commitment to engaging with the investment community and highlighting its innovative pipeline.